| pubmed-article:17551397 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17551397 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17551397 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:17551397 | lifeskim:mentions | umls-concept:C1516477 | lld:lifeskim |
| pubmed-article:17551397 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:17551397 | lifeskim:mentions | umls-concept:C0023449 | lld:lifeskim |
| pubmed-article:17551397 | lifeskim:mentions | umls-concept:C0071568 | lld:lifeskim |
| pubmed-article:17551397 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:17551397 | pubmed:dateCreated | 2007-6-6 | lld:pubmed |
| pubmed-article:17551397 | pubmed:abstractText | The Pediatric Oncology Group 9203 pilot protocol was designed to determine the feasibility of delivering 29 biweekly doses of polyethylene glycol (PEG)-L-asparaginase, on a backbone of intensive multiagent antimetabolite-based consolidation and maintenance in higher risk B-precursor acute lymphoblastic leukemia. Between June 1992 and August 1993, 34 patients were enrolled on this limited institution pilot. The 5-year event-free survival (+/-standard error) and overall survival (+/-standard error) were 68+/-8% and 76+/-7%, respectively. Excessive toxicities attributed to PEG-L-asparaginase and myelosuppression associated with cytosine arabinoside were encountered during consolidation resulting in early study closure and modification of therapy for those already enrolled. Ninety-two percent of methotrexate/cytosine arabinoside cycles were associated with grades 3 to 4 myelosuppression, and 24% resulted in delays in therapy of more than 7 days. Fifteen PEG-L-asparaginase related toxicities occurred in 13 patients (8 allergy, 4 pancreas, 2 central nervous system, and 1 hemorrhage). Intensification of therapy with PEG-L-asparaginase resulted in event-free survival and overall survival comparable to other studies of the same time period without the use of agents associated with long-term complications, such as anthracyclines, epipodophyllotoxins, and alkylating agents. However, excessive toxicity occurred with intensified PEG-L-asparaginase and antimetabolite based therapy delivered on this schedule. | lld:pubmed |
| pubmed-article:17551397 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551397 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551397 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551397 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17551397 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551397 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17551397 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551397 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551397 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551397 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551397 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17551397 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17551397 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:17551397 | pubmed:issn | 1077-4114 | lld:pubmed |
| pubmed-article:17551397 | pubmed:author | pubmed-author:WangChenguang... | lld:pubmed |
| pubmed-article:17551397 | pubmed:author | pubmed-author:DevidasMeenak... | lld:pubmed |
| pubmed-article:17551397 | pubmed:author | pubmed-author:CamittaBruce... | lld:pubmed |
| pubmed-article:17551397 | pubmed:author | pubmed-author:KurtzbergJoan... | lld:pubmed |
| pubmed-article:17551397 | pubmed:author | pubmed-author:AsselinBarbar... | lld:pubmed |
| pubmed-article:17551397 | pubmed:author | pubmed-author:ShusterJonath... | lld:pubmed |
| pubmed-article:17551397 | pubmed:author | pubmed-author:Children's... | lld:pubmed |
| pubmed-article:17551397 | pubmed:author | pubmed-author:ChauvenetAlle... | lld:pubmed |
| pubmed-article:17551397 | pubmed:author | pubmed-author:SalzerWanda... | lld:pubmed |
| pubmed-article:17551397 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17551397 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:17551397 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17551397 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17551397 | pubmed:pagination | 369-75 | lld:pubmed |
| pubmed-article:17551397 | pubmed:dateRevised | 2011-10-6 | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:meshHeading | pubmed-meshheading:17551397... | lld:pubmed |
| pubmed-article:17551397 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17551397 | pubmed:articleTitle | Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. | lld:pubmed |
| pubmed-article:17551397 | pubmed:affiliation | Keesler Medical Center, Keesler AFB, Biloxi, MS, USA. Wanda.Salzer@amedd.army.mil | lld:pubmed |
| pubmed-article:17551397 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17551397 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:17551397 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
